LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Akcijų sąrašas・Becton Dickinson and Co

Becton Dickinson and Co

Uždarymo kaina

SektoriusSveikatos priežiūra

147.7 0.8

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

147

Max

147.72

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-692M -310M
Pardavimai	-538M 4.7B
P/E Sektoriaus vid.	24.8 49.701
Pelnas, tenkantis vienai akcijai	2.9
Dividendų pajamingumas	2.91
Pelno marža	-6.576
Darbuotojai	60,000
EBITDA	-1B 189M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+23.42% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	2.91% 2.39%
Kitas uždarbis	2026-08-06
Kitas dividendų mokėjimo data	2026-06-30
Kita Ex Dividend data	2026-06-09

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-2.4B 39B
Ankstesnė atidarymo kaina	146.9
Ankstesnė uždarymo kaina	147.7

Naujienos nuotaikos

By Acuity

24%

76%

43 / 345 reitingas Healthcare

Becton Dickinson and Co Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-07 11:19; UTC

Uždarbis

Becton Dickinson Boosts Outlook as 3Q Results Beat Estimates

2025-07-14 14:26; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal -- 2nd Update

2025-07-14 11:08; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal -- Update

2025-07-14 10:37; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal

2025-08-07 10:32; UTC

Uždarbis

Becton Dickinson Expects to Complete Remaining $250M of $1B Share-Buyback Commitment by End FY25 >BDX

2025-08-07 10:31; UTC

Uždarbis

Becton Dickinson Backs FY25 View of Rev $21.8B-$21.9B >BDX

2025-08-07 10:31; UTC

Uždarbis

Becton Dickinson Had Seen FY25 Adjusted EPS $14.06-$14.34 >BDX

2025-08-07 10:30; UTC

Uždarbis

Becton Dickinson Raises FY25 View To Adj EPS $14.30-Adj EPS $14.45 >BDX

2025-08-07 10:30; UTC

Uždarbis

Becton Dickinson 3Q Adj EPS $3.68 >BDX

2025-08-07 10:30; UTC

Uždarbis

Becton Dickinson 3Q Net $574M >BDX

2025-08-07 10:30; UTC

Uždarbis

Becton Dickinson 3Q Rev $5.51B >BDX

2025-08-07 10:30; UTC

Uždarbis

Becton Dickinson 3Q EPS $2.00 >BDX

2025-07-15 18:32; UTC

Įsigijimai, susijungimai, perėmimai

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

2025-07-15 18:31; UTC

Įsigijimai, susijungimai, perėmimai

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

2025-07-14 16:12; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

2025-07-14 15:06; UTC

Įsigijimai, susijungimai, perėmimai

Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit -- Barrons.com

2025-07-14 14:11; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5B Deal -- 2nd Update

2025-07-14 10:53; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal -- Update

2025-07-14 10:22; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal

2025-07-14 10:22; UTC

Įsigijimai, susijungimai, perėmimai

Waters To Assume About $4 Billion Incremental Debt >WAT BDX

2025-07-14 10:22; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson to Get $4 Billion Cash Distribution Prior to Closing >WAT BDX

2025-07-14 10:21; UTC

Įsigijimai, susijungimai, perėmimai

Waters Holders to Own 60.8% of Combined Company, Becton Dickinson Holders to Own 39.2% >WAT BDX

2025-07-14 10:20; UTC

Įsigijimai, susijungimai, perėmimai

Waters, Becton Dickinson: Combined Company to Have About $9 Billion Revenue, $3.3 Billion Adjusted Ebitda >WAT

2025-07-14 10:19; UTC

Įsigijimai, susijungimai, perėmimai

Correct: Waters, Becton Dickinson See About $290 Million Revenue Synergies by Year Five >WAT BDX

2025-07-14 10:19; UTC

Įsigijimai, susijungimai, perėmimai

Waters, Becton Dickinson See About $345 Million Annualized Ebitda Synergies by 2030 >WAT BDX

2025-07-14 10:18; UTC

Įsigijimai, susijungimai, perėmimai

Waters, Becton Dickinson See About $290 Revenue Cost Synergies by Year Five >WAT BDX

2025-07-14 10:18; UTC

Įsigijimai, susijungimai, perėmimai

Waters, Becton Dickinson See About $200 Million Cost Synergies by Year Three >WAT BDX

2025-07-14 10:17; UTC

Įsigijimai, susijungimai, perėmimai

Waters: Becton Dickinson Deal Doubles Total Addressable Market to About $40 Billion >WAT

2025-07-14 10:16; UTC

Įsigijimai, susijungimai, perėmimai

Waters, Becton Dickinson Deal Structured as Reverse Morris Trust >WAT BDX

2025-07-14 10:16; UTC

Įsigijimai, susijungimai, perėmimai

Waters, Becton Dickinson Deal Valued at About $17.5 Billion >WAT BDX

Akcijų palyginimas

Kainos pokytis

Becton Dickinson and Co Prognozė

Kainos tikslas

By TipRanks

23.42% į viršų

12 mėnesių prognozė

Vidutinis 182.2 USD 23.42%

Aukščiausias 221 USD

Žemiausias 159 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Becton Dickinson and Co kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Becton Dickinson and Co akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

43 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.